Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis
Details
Publication Year 2023-09,Volume 64,Issue #9,Page 1600-1604
Journal Title
Leukemia & Lymphoma
Publication Type
Research article
Publisher
Taylor & Francis
Keywords
Humans; *Pre-Exposure Prophylaxis; *COVID-19/prevention & control; Antibodies, Monoclonal
Department(s)
Clinical Haematology; Ambulatory Services; Infectious Diseases
PubMed ID
37341732
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-15 06:57:58
Last Modified: 2024-07-09 05:30:59

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙